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ABSTRACT 
Objective: To examine pregnancy outcomes and pregnancy-related health service 
utilisation among women with rare autoimmune diseases. 
Methods:  This population-based cohort study of an Australian obstetric population (New 
South Wales 2001-2011) used birth records linked to hospital records for identification of 
rare autoimmune diseases including systemic vasculitis, vasculitis limited to skin, 
systemic sclerosis, dermatopolymyositis and other systemic involvement of connective 
tissue. We excluded births to women with systemic lupus erythematosus or rheumatoid 
arthritis and births >6 months before the first documented diagnosis of the rare 
autoimmune disease. Modified Poisson regression was used to compare study outcomes 
between women with autoimmune diseases and the general obstetric population. 
Results: There were 991,701 births including 409 (0.04%) births to 293 women with rare 
autoimmune diseases. Of the 409 pregnancies, 202 (49%) delivered by cesarean delivery 
and 72 (18%) were preterm; these rates were significantly higher than those in the general 
obstetric population (28% and 7% respectively). Compared to the general population, 
women with autoimmune diseases had higher rates of hypertensive disorders, antepartum 
hemorrhage and severe maternal morbidity, and required longer hospitalization at delivery 
and more hospital admissions and tertiary obstetric care. Compared to other infants, those 
whose mothers had a rare autoimmune disease were at increased risk of admission to 
neonatal intensive care unit, severe neonatal morbidity and perinatal death. 
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Conclusions: Women with rare autoimmune diseases were at increased risk of having 
both maternal complications and adverse neonatal outcomes; their pregnancies should be 
closely monitored.  
Key words: Autoimmune disease; pregnancy outcome; pregnancy; population-based 
study; record linkage 
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BACKGROUND  
Autoimmune diseases, such as systemic lupus erythematosus (SLE), rheumatoid arthritis 
(RA), primary Sjögren’s syndrome, vasculitis, systemic sclerosis and 
dermatopolymyositis, are characterised by an abnormal immunological reaction against 
one’s own cells, tissues and/or organs resulting in inflammation and damage. These 
disorders are chronic illnesses and occur frequently among women of childbearing age.1;2 
They are usually treated with anti-inflammatory, immunosuppressive or disease modifying 
drugs.3 Women with autoimmune diseases are therefore concerned about possible 
teratogenic risk from the treating drugs, adverse neonatal outcomes from the disease itself, 
maternal complications and pregnancy-related disease flares. Consequently, some women 
consider avoiding pregnancy.4;5  
 
Many studies have investigated the impact of the more common autoimmune diseases, 
such as SLE and RA, on women’s pregnancy outcomes, indicating different effects of 
these two autoimmune diseases.1;6-11 Women with SLE may experience recurrent 
pregnancy loss and approximately 50% have a disease flare-up during pregnancy with 
potential negative impacts on pregnancy outcomes.7;10 By conceiving a baby during low 
lupus activity periods, pregnancy complications such as fetal loss, infants with congenital 
heart block, premature delivery, preeclampsia and intrauterine growth restriction, can be 
greatly reduced.2;8  
 
In contrast, women with RA generally have reduced activity of the disease during 
pregnancy.1 Also, they have good overall outcomes if potentially teratogenic drugs such as 
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methotrexate have not been used at the time of conception or during the pregnancy.1 
However, an increased risk of fetal growth restriction has been observed in several 
studies.6;11 
 
Other autoimmune diseases, such as systemic vasculitis, vasculitis limited to skin, 
systemic sclerosis, dermatopolymyositis, and other systemic involvement of connective 
tissue including primary Sjögren’s syndrome, are relatively rare in women of childbearing 
age.12 There are only limited studies investigating pregnancy outcomes of women with 
these rare autoimmune diseases. In general, these studies are small case-control studies or 
case series.13-16 Further investigations are therefore needed of the pregnancy outcomes of 
women with these rare autoimmune diseases. The aim of this population-based cohort 
study is to compare pregnancy outcomes and pregnancy related health service utilization 
between women with these autoimmune diseases and the general obstetric population in 
New South Wales (NSW), Australia.  
 
METHODS 
Data sources and study population 
Two population health datasets were used: the New South Wales (NSW) Perinatal Data 
Collection (‘birth data’) and the NSW Admitted Patient Data Collection (‘hospital data’). 
The birth data include all live births or stillbirths (≥20 weeks gestation or ≥400 grams 
birth weight) in NSW. Information collected in the birth data by the attending doctor or 
midwife includes demographics, number of previous births and maternal health, 
pregnancy, labor, delivery, and perinatal outcomes. The hospital data covers every 
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inpatient admission in NSW, and includes demographic and episode related data. Data 
from the medical records are coded according to the tenth revision of the International 
Classification of Diseases Australian Modification (ICD-10-AM) and the affiliated 
Australian Classification of Health Interventions.17 Record linkage of birth data and 
hospital data (both mother and baby) by the Centre for Health Record Linkage 
(CHeReL).18  The CHeReL undertakes quality assurance for all record linkage and 
assesses the linkage quality by manually reviewing personal identifiers for a sample of the 
records obtained for linkage. Linkage proportions for maternal records are >98% and for 
this study, the CHeReL reported the linkage quality as 3 per 1000 false-positive links and 
less than 5 per 1000 false-negative links. Only de-identified data were made available to 
researchers. 
 
Women were included in this study if they gave birth in NSW between January 1, 2001 
and December 31, 2011. Their records in the birth dataset for this study period were 
linked to their medical records in the hospital data from July 1, 2000 to June 30, 2012. 
Births among women with SLE (ICD-10-AM code: M32) or RA (ICD-10-AM codes: 
M05 and M06) recorded in the hospital data were excluded from the study. The exposure 
of interest was rare autoimmune diseases (i.e. systemic vasculitis, vasculitis limited to 
skin, systemic sclerosis, dermatopolymyositis and other systemic involvement of 
connective tissue) that could potentially affect pregnancy outcomes and this was 
considered to be diagnoses prior to, during or within 6 months of the index birth. 
Consequently we excluded births among women with rare autoimmune diseases that 
occurred more than six months before the first diagnosis documented in the linked dataset. 
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The remaining births among women with the rare autoimmune diseases were compared to 
births among other women in the dataset.  
 
Ascertaining exposures, outcomes and covariates  
Both birth data and hospital data were used for the ascertainment of study variables. Up to 
20 diagnoses and/or 20 procedures in each hospital record were used for identification of 
study exposure (the autoimmune diseases) and outcomes. 
 
Rare autoimmune diseases 
The ICD-10-AM codes used for the identification of the rare autoimmune diseases were: 
L95 for vasculitis limited to skin, both M30 (polyarteritis nodosa and related conditions) 
and M31 (other necrotising vasculopathies) for systemic vasculitis, M33 for 
dermatopolymyositis, M34 for systemic sclerosis and M35 for other systemic involvement 
of connective tissue. A diagnosis could be recorded in antenatal, birth or postpartum (up to 
6 months after the delivery) hospital records as well as records before pregnancy. 
 
Outcomes 
Maternal outcomes ascertained from the linked dataset included cesarean delivery, labor 
induction, pregnancy hypertension (gestational hypertension or preeclampsia), gestational 
diabetes, antepartum hemorrhage (including placental abruption), postpartum hemorrhage, 
severe perineal trauma (3rd-4th degree tear) and severe maternal morbidity (a composite 
indicator for measuring major maternal morbidity19). Neonatal outcomes included preterm 
birth (<37 weeks gestation), small for gestational age (birth weight<10th percentile for age 
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and sex20), admission to neonatal intensive care unit, severe neonatal morbidity (a 
composite indicator for measuring severe adverse neonatal outcomes21), major congenital 
anomalies (e.g. congenital heart block, spina bifida etc22) and perinatal mortality (stillbirth 
or neonatal death). Health service utilization outcomes were use of assisted reproductive 
technology, obstetric hospital type (tertiary, urban or rural), number of antenatal hospital 
admissions, length of hospital stay for birth admission, and types of postpartum 
admissions (any, gastrointestinal or venous thromboembolism cause). 
 
Covariates  
We also ascertained the following information from the linked dataset: maternal age at 
delivery, country of birth (Australia or New Zealand, Europe or North America, Asia, 
other countries), socio-economic status based on residential postcode (Index of Relative 
Socio-economic Disadvantage23), maternal residence at delivery (urban or rural), smoking 
during pregnancy, chronic hypertension, pregestational diabetes, morbid obesity, number 
of previous births, plurality, inter-pregnancy interval (interval between first and second 
births minus gestational age of the second birth) and any abortion or miscarriage (before 
20 weeks gestation) during the study period. 
 
Data analysis 
Descriptive statistics were used to summarise characteristics at birth for the study women 
by status of the studied diseases. Pregnancy outcomes were compared between women 
with the rare autoimmune diseases and those without (the general obstetric population) 
using modified Poisson regression with robust error variance24 to estimate relative risks 
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(RRs) with 95% confidence intervals (CIs). For some uncommon outcomes the ‘modified 
Poisson’ models failed to converge. In these instances, an adjusted odds ratios (OR and 
95% CI) was calculated using a logistic regression model. For uncommon outcomes, the 
OR provides a good estimate of the relative risk. The lack of independence in study 
outcomes for multiple pregnancies to the same woman during the study period was dealt 
with using the generalised estimating equations (GEE) approach. Results were reported 
for all women with the rare autoimmune diseases as well as by disease specific sub-group. 
The regression analyses were performed with and without adjusting for known 
determinants of pregnancy outcomes such as maternal age, country of birth, socio-
economic status, maternal residence, hypertension, diabetes, smoking during pregnancy, 
parity, plurality. Health service utilization related to pregnancy during the study period 
was also reported for women with autoimmune diseases and the general obstetric 
population and the differences between the two groups were compared using the chi-
square test or Wilcoxon two-sample test where appropriate.   
 
The study was approved by the NSW Population and Health Services Research Ethics 
Committee (2012-12-430). 
 
RESULTS 
During the study period, 629,954 women had 994,084 births including 2,056 births to 
1,268 women with either SLE or RA. These SLE or RA births were not included in this 
study. After further excluding 327 births that occurred more than six months before the 
first rare autoimmune disease diagnosis in the dataset, 293 women with the rare 
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autoimmune diseases had 409 births: 235 births to 164 women with other systemic 
involvement of connective tissue, 85 births to 60 women with systemic vasculitis, 53 
births to 42 women with systemic sclerosis, 24 births to 18 women with vasculitis limited 
to skin, and 17 births to 13 women with dermatopolymyositis. The remaining 628,393 
women had 991,292 births and provided the reference population for the study.  
 
Characteristics at birth for the study women are presented in Table 1. For women with 
autoimmune diseases and the general obstetric population, the percentages who had an 
abortion or miscarriage over the study period were 26.3% and 16.7% respectively; and the 
percentages who used assisted reproductive technology for pregnancy were 3.7% and 
2.3% respectively. Median age at first birth (or any birth) was 31.7 (33.0) years for 
women with autoimmune diseases and 29.0 (30.7) years for the general obstetric 
population. For women who had both a first and second birth during the study period, 100 
women with autoimmune diseases and 201,729 without, there was little difference in the 
interpregnancy interval (median 550 days and 561 days, respectively). 
 
Compared to the general obstetric population, women with the autoimmune diseases had 
significantly higher incidence per pregnancy of pregnancy hypertension, antepartum 
hemorrhage and severe maternal morbidity; and they were significantly more likely to 
have a planned delivery, by labor induction (47.6% versus 30.2%) or prelabor cesarean 
delivery (31.8% versus 16.2%), even after adjusting for confounders including socio-
economic status (Table 2). No differences were observed in gestational diabetes, 
postpartum hemorrhage and 3rd-4th degree tear between the two groups.  
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Among the 409 births, there were 15 (3.7%) perinatal deaths and 15 (3.7%) infants had 
major congenital anomalies. The corresponding rates among births to the general obstetric 
population were 0.8% (n=8,239) and 2.2% (n=21,736) respectively. For women with 
autoimmune diseases, the adjusted relative risk was 4.70 (95% CI: 2.87 to 7.69) for 
perinatal mortality and 1.32 (95% CI: 0.77 to 2.25) for major congenital anomalies. Five 
(one-third) of the anomalies were cardiac including congenital heart block, other specified 
congenital formation of heart and ventricular septal defect.  Compared to infants from the 
general obstetric population, infants of women with autoimmune diseases were also more 
likely to be born preterm (medically indicated or spontaneous) or to be admitted to a 
NICU, and had a higher rate of severe neonatal morbidity (Table 3). There was no 
difference between the two groups in risks of infants being small for gestational age 
(Table 3) for women with the autoimmune diseases compared with the general obstetric 
population.  
 
There was greater health service utilization by women with the autoimmune diseases than 
in the general obstetric population, including longer maternal hospital stay for birth 
admission, more hospital admissions during antenatal and postpartum periods, and higher 
rate of use of tertiary hospital for obstetric care (Table 4).  
 
CONCLUSIONS 
This study showed women with a rare autoimmune disease, such as other systemic 
involvement of connective tissue including primary Sjögren’s syndrome, systemic 
vasculitis, systemic sclerosis, vasculitis limited to skin or dermatopolymyositis, had 
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poorer pregnancy outcomes compared to the general obstetric population. They were at 
increased risk of hypertensive disorders, hemorrhage and severe maternal morbidity; and 
their infants were at increased risk of preterm birth, NICU admission, severe neonatal 
morbidity and perinatal death. There was little evidence that a specific rare autoimmune 
disease group would depart from the general findings based on the analyses of all the rare 
autoimmune diseases women together (see Tables 2 and 3). Without further evidence, 
pregnancies to women with the rare autoimmune diseases including vasculitis limited to 
skin, should be considered as high-risk pregnancies.  
 
Our findings are consistent with recent studies of pregnancy outcomes from women with 
these autoimmune diseases.14;15;25;26 In a case-control study of 28 primary Sjögren’s 
syndrome births,14 two (7%) births resulted in infants with congenital heart block. The 
primary Sjögren’s syndrome pregnancies also had increased risks of spontaneous abortion 
(33%), preterm birth (33%) and cesarean delivery (44%). In 2011, an online survey found 
74 pregnancies after the diagnosis of vasculitis had significantly higher rates of pregnancy 
loss (33.8% vs 22.4%; P =0.04) and preterm delivery (23.3% vs 11.4%; P = 0.03) 
compared to 496 pregnancies before diagnosis.26 In a study of 149 systemic sclerosis 
births among the 2,893,904 deliveries from approximately 20% of community hospitals in 
the United States of America during 2002-2004, Chakravarty et al reported systemic 
sclerosis was associated with increased risks of antenatal hospitalisation, hypertensive 
disorders, intrauterine growth restriction, and cesarean delivery as well as increased length 
of hospital stay.25  
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Pagnoux et al reported detailed pregnancy outcomes of 20 pregnancies including 6 
conceived during disease activity to 12 French women with systemic necrotising 
vasculitides over the 15 years prior to 2010.15 Of the 20 pregnancies, 6 (30%) ended in 
abortion or miscarriage and among the remaining 14 pregnancies, 8 (57%) resulted in 
preterm delivery, 7 (50%) delivered by cesarean delivery including 3 emergency 
deliveries due to life-threatening complications, 6 (43%) required short stays (<7 days) in 
neonatal units, 5 (36%) experienced premature rupture of membranes, 1 (7%) had 
hypertension, renal deterioration or placenta praevia. However, none of the children had 
yet experienced vasculitis manifestations or other systemic disease by the time of the 
publication. They concluded that pregnancies to women with systemic necrotising 
vasculitides should be closely monitored as life-threatening manifestations could occur 
during pregnancy especially in women with vasculitis-related cardiac or renal damage. 
Compared to the general obstetric population, women with the rare autoimmune diseases 
in our study had a higher rate of tertiary hospital deliveries, longer hospital stay for birth 
admission and greater numbers of antenatal and postpartum admissions, indicating these 
had been treated as high-risk pregnancies. Our results also suggest women with the rare 
autoimmune diseases needed close monitoring over their pregnancy. 
 
It is noteworthy that major congenital anomalies occurred in about 1 in 25 pregnancies to 
women with the rare autoimmune diseases in our study and one third of the 15 major birth 
defect cases among our study patients were related to congenital heart disorders. Anti 
Ro/SS-A and/or anti La/SS-B autoantibodies, which are associated with infant congenital 
heart block, could present in women with various autoimmune diseases including 
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Sjögren’s syndrome and systemic sclerosis.27 Pregnant women with anti Ro/SS-A or anti 
La/SS-B autoantibody should be closely monitored. Tincani et al28 suggested monitoring 
of the fetuses with serial echocardiography weekly starting from 16 to 26 weeks gestation 
and then every other week until about 34 weeks. When incomplete congenital heart block 
is diagnosed in utero, the mothers should be treated with fluorinated corticosteroids to 
reduce the inflammation of the fetal heart and prevent its progression. In a recent review 
of fetal outcomes among women with autoimmune diseases, Carvalheiras et al1 concluded 
there was increasingly the hope that fetal outcome would be optimised if pregnancy 
occurred after disease remission for at least 6 months and the pregnant woman had been 
cared for with specialised interdisciplinary support including adequate fetal monitoring, 
routine obstetric ultrasound, biophysical profile, umbilical uterine artery Doppler blood-
flow waveforms and fetal echocardiography. 
 
This study has certain strengths and limitations. The strengths include the use of large 
linked population health datasets over a long time period, in which women could be 
tracked over time in different hospitals. The pregnancy and birth outcome data utilised in 
this study have been shown to be accurate and reliable when validated against medical 
records.29-32 Also, we were able to adjust for many maternal demographic characteristics 
and perinatal factors including smoking during pregnancy, parity and multiple pregnancy. 
A major limitation of our study is the likely under ascertainment of autoimmune disease 
from hospital records. Hospital data only record diseases or conditions that require 
hospitalisation or that affect a hospital admission. Our study patients would presumably be 
among those with the most active or severe disease, so the findings of this study might be 
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expected to present the worst case scenario. On the other hand, it is possible that we have 
underestimated pregnancy losses, with only those requiring hospitalisation included in our 
data. Nevertheless, the increased risk of abortion or miscarriage observed among the study 
patients would be true unless there were reasons to believe abortions or miscarriages in 
women with the autoimmune diseases were more likely to be hospitalised than in the 
general obstetric women. Unfortunately, our datasets do not include information on 
autoantibody profile, use of drugs, duration and severity of disease, or disease activity 
around the time of pregnancy or during pregnancy so we could not explore their impacts. 
 
In summary, women with rare autoimmune diseases are at increased risk of having both 
maternal complications and adverse neonatal outcomes. Pregnancy in rare autoimmune 
diseases therefore requires close co-operation between women and their health care 
providers.  
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Table 1: Characteristics at birth for women who gave birth in NSW by status of rare 
autoimmune diseases 
 General obstetric 
population 
N=991,292 births 
to 628,393 women 
Women with rare 
autoimmune diseases* 
N=409 births  
to 293 women 
Maternal age at birth (year), median(range) 30.7 (12.0-56.2)  33.0 (16.7-45.9) 
Country of birth, n(%)   
    Australia/New Zealand 722,035 (73.0) 314 (77.0) 
    Europe, USA or Canada 61,892 (6.3) 22 (5.4) 
    Asia 127,104 (12.9) 44 (10.8) 
    Other 75,523 (7.8) 28 (6.9) 
SES†, n(%)   
    Most disadvantaged 215,242 (22.0) 70 (17.2) 
    Disadvantaged 196,157 (20.0) 58 (14.2) 
    Average 204,336 (20.8) 103 (25.3) 
    Advantaged 179,903 (18.4) 84 (20.6) 
    Most advantaged 184,882 (18.9) 93 (22.8) 
Urban residence at delivery, n(%) 689,387 (69.5) 303 (74.1) 
Nullipara, n(%) 417,103 (42.1) 165 (40.3) 
Number of births at last birth, mean (standard 
deviation) 
2.15 (1.20) 2.16 (1.28) 
Plurality, n(%) 15,429 (1.6) 5 (1.2) 
Maternal hypertension, n(%) 6,835 (0.7) 9 (2.2) 
23 
 
Chronic diabetes, n(%) 5,629 (0.6) 4 (1.0) 
Morbid obesity, n(%) 3,126 (0.3) 1 (0.2) 
Smoking during pregnancy, n(%) 135,248 (13.6) 44 (10.8) 
Use of assisted reproductive technology, n(%) 22,368 (2.3) 15 (3.7) 
Abortion/miscarriage n(%) 105,125 (16.7) 77 (26.3) 
* Including other systemic involvement of connective tissue, systemic vasculitis, systemic 
sclerosis, vasculitis limited to skin and dermatopolymyositis. 
† Socio-economic status using Index of Relative Socio-economic Disadvantage for Areas. 
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Table 2    Relative risks (RR) of maternal and pregnancy outcomes for women with rare 
autoimmune diseases 
Outcome variable 
  Exposure (autoimmune disease) group 
Outcome 
No. (%) 
Unadjusted RR 
(95% CI) 
Adjusted RR* 
(95% CI) 
Pregnancy hypertension    
  Other systemic involvement of connective tissue 38 (16.2) 1.80 (1.31, 2.46) 1.65 (1.20, 2.25) 
  Systemic vasculitis 17 (20.0) 2.26 (1.41, 3.62) 2.29 (1.44, 3.65) 
  Systemic sclerosis 4 (7.6) 0.86 (0.34, 2.21) 0.85 (0.33, 2.20) 
  Vasculitis limited to skin 2 (8.3) 1.04 (0.27, 3.95) 0.91 (0.24, 3.47) 
  Dermatopolymyositis 4 (23.5) 2.92 (1.22, 6.97) 2.94 (1.31, 6.58) 
  Any of above 63 (15.4) 1.73 (1.35, 2.21) 1.64 (1.29, 2.09) 
  General obstetric population 89,035 (9.0) 1.00 1.00 
Gestational diabetes    
  Other systemic involvement of connective tissue 25 (10.6) 1.68 (1.09, 2.58) 1.56 (1.01, 2.41) 
  Systemic vasculitis 5 (5.9) 1.17 (0.50, 2.75) 0.98 (0.43, 2.25) 
  Systemic sclerosis 3 (5.7) 1.06 (0.35, 3.20) 0.92 (0.30, 2.83) 
  Vasculitis limited to skin 0 (0) - - 
  Dermatopolymyositis 0 (0) - - 
  Any of above 33 (8.1) 1.34 (0.93, 1.93) 1.24 (0.86, 1.79) 
  General obstetric population 57,337 (5.8) 1.00 1.00 
Antepartum hemorrhage    
  Other systemic involvement of connective tissue 12 (5.1) 1.72 (0.99, 3.01) 1.73 (1.00, 3.01) 
  Systemic vasculitis 5 (5.9) 1.96 (0.72, 5.36) 1.93 (0.72, 5.18) 
  Systemic sclerosis 4 (7.6) 2.51 (0.98, 6.42) 2.37 (0.97, 5.77) 
  Vasculitis limited to skin 1 (4.2) 1.30 (0.22, 7.76) 1.31 (0.21, 8.13) 
  Dermatopolymyositis 2 (11.8) 3.97 (1.04, 15.2) 3.87 (1.04, 14.4) 
  Any of above 23 (5.6) 1.88 (1.24, 2.85) 1.87 (1.24, 2.81) 
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  General obstetric population 30,092 (3.0) 1.00 1.00 
Labor Induction†    
  Other systemic involvement of connective tissue 86 (53.4) 1.72 (1.48, 2.00) 1.50 (1.29, 1.75) 
  Systemic vasculitis 27 (43.6) 1.42 (1.05, 1.93) 1.27 (0.95, 1.69) 
  Systemic sclerosis 10 (34.5) 1.13 (0.67, 1.90) 1.10 (0.70, 1.73) 
  Vasculitis limited to skin 4 (22.2) 0.73 (0.32, 1.64) 0.78 (0.34, 1.77) 
  Dermatopolymyositis 4 (44.4) 1.51 (0.78, 2.91) 1.46 (0.89, 2.40) 
  Any of above 131 (47.0) 1.52 (1.33, 1.73) 1.37 (1.21, 1.55) 
  General obstetric population 250,983 (30.2) 1.00 1.00 
Cesarean delivery (any)    
  Other systemic involvement of connective tissue 114 (48.5) 1.76 (1.47, 2.10) 1.50 (1.28, 1.76) 
  Systemic vasculitis 35 (41.2) 1.53 (1.14, 2.05) 1.35 (1.03, 1.76) 
  Systemic sclerosis 34 (64.2) 2.37 (1.89, 2.98) 2.09 (1.68, 2.58) 
  Vasculitis limited to skin 9 (37.5) 1.39 (0.76, 2.55) 1.34 (0.76, 2.35) 
  Dermatopolymyositis 15 (88.2) 3.20 (2.65, 3.86) 3.12 (2.46, 3.96) 
  Any of above 202 (49.4) 1.81 (1.57, 2.08) 1.58 (1.41, 1.77) 
  General obstetric population 279,766 (28.2) 1.00 1.00 
Planned (prelabor) cesarean delivery    
  Other systemic involvement of connective tissue 74 (31.5) 1.86 (1.49, 2.33) 1.59 (1.28, 1.98) 
  Systemic vasculitis 23 (27.1) 1.59 (1.07, 2.36) 1.44 (0.98, 2.09) 
  Systemic sclerosis 24 (45.3) 2.76 (2.01, 3.77) 2.33 (1.66, 3.26) 
  Vasculitis limited to skin 6 (25.0) 1.52 (0.70, 3.30) 1.56 (0.74, 3.28) 
  Dermatopolymyositis 8 (47.1) 2.92 (1.69, 5.03) 3.15 (1.94, 5.12) 
  Any of above 130 (31.8) 1.90 (1.61, 2.24) 1.66 (1.42, 1.95) 
  General obstetric population 160,812 (16.2) 1.00 1.00 
3rd-4th degree tear‡    
  Other systemic involvement of connective tissue 2 (1.7) 0.46 (0.16, 2.59) 0.73 (0.19, 2.85) 
  Systemic vasculitis 0 (0) - - 
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  Systemic sclerosis 1 (5.3) 1.95 (0.31, 12.2) 2.88 (0.40, 20.7) 
  Vasculitis limited to skin 1 (6.7) 2.62 (0.38, 18.1) 2.47 (0.39, 15.6) 
  Dermatopolymyositis 0 (0) - - 
  Any of above 4 (1.9) 0.75 (0.28, 1.98) 0.81 (0.31, 2.12) 
  General obstetric population 18,348 (2.6) 1.00 1.00 
Postpartum hemorrhage    
  Other systemic involvement of connective tissue 22 (9.4) 0.97 (0.62, 1.50) 1.04 (0.69, 1.55) 
  Systemic vasculitis 11 (12.9) 1.35 (0.73, 2.51) 1.44 (0.81, 2.56) 
  Systemic sclerosis 10 (18.9) 1.97 (1.11, 3.52) 1.84 (1.05, 3.23) 
  Vasculitis limited to skin 3 (12.5) 1.22 (0.33, 4.58) 1.46 (0.39, 5.44) 
  Dermatopolymyositis 2 (11.8) 1.22 (0.34, 4.39) 1.25 (0.33, 4.68) 
  Any of above 47 (11.5) 1.19 (0.85, 1.66) 1.26 (0.95, 1.66) 
  General obstetric population 86,347 (8.7) 1.00 1.00 
Severe maternal morbidity    
  Other systemic involvement of connective tissue 14 (6.0) 3.16 (1.80, 5.55) 3.43 (2.02, 5.85) 
  Systemic vasculitis 10 (11.8) 6.23 (3.49, 11.1) 6.09 (3.51, 10.6) 
  Systemic sclerosis 5 (9.4) 5.07 (2.15, 11.9) 5.06 (2.34, 10.9) 
  Vasculitis limited to skin 0 (0) - - 
  Dermatopolymyositis 0 (0) - - 
  Any of above 28 (6.9) 3.63 (2.42, 5.47) 3.80 (2.63, 5.48) 
  General obstetric population 15,914 (1.6) 1.00 1.00 
* Adjusted for maternal age, country of birth, socio-economic status, maternal residence, chronic 
hypertension, pregestational diabetes, smoking during pregnancy, parity and plurality.  
† Excludes planned cesarean deliveries. 
‡ Excludes cesarean deliveries. 
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Table 3    Relative risks (RR) of neonatal outcomes for women with rare autoimmune 
diseases 
Outcome variable 
  Exposure (autoimmune disease) group 
Outcome  
No. (%) 
Unadjusted RR  
(95% CI) 
Adjusted! RR 
(95% CI) 
Preterm birth (<37 weeks)    
  Other systemic involvement of connective tissue 30 (12.8) 2.01 (1.42, 2.84) 1.92 (1.36, 2.72) 
  Systemic vasculitis 21 (24.7) 3.94 (2.71, 5.73) 3.73 (2.63, 5.30) 
  Systemic sclerosis 16 (30.2) 4.80 (3.03, 7.61) 4.19 (2.56, 6.86) 
  Vasculitis limited to skin 3 (12.5) 1.93 (0.50, 7.37) 2.07 (0.56, 7.65) 
  Dermatopolymyositis 6 (35.3) 5.64 (2.66, 11.9) 5.48 (2.46, 12.2) 
  Any of above 72 (17.6) 2.79 (2.23, 3.50) 2.65 (2.12, 3.31) 
  General obstetric population 65,268 (6.6) 1.00 1.00 
Medically indicated preterm birth (<37 weeks)    
  Other systemic involvement of connective tissue 18 (7.7) 2.94 (1.83, 4.74)† 2.61 (1.58, 4.33)† 
  Systemic vasculitis 18 (21.2) 9.52 (5.62, 16.1)† 8.59 (5.00, 14.7)† 
  Systemic sclerosis 9 (17.0) 7.52 (3.57, 15.9)† 6.81 (3.01, 15.4)† 
  Vasculitis limited to skin 2 (8.3) 3.19 (0.77, 13.2)† 4.08 (0.90, 18.4)† 
  Dermatopolymyositis 5 (29.4) 15.3 (5.23, 44.7)† 15.8 (4.69, 53.0)† 
  Any of above 48 (11.7) 4.76 (3.51, 6.45)† 4.33 (3.13, 6.00)† 
  General obstetric population 27,480 (2.8) 1.00† 1.00† 
Spontaneous preterm birth (<37 weeks) ‡    
  Other systemic involvement of connective tissue 12 (16.0) 2.30 (1.33, 3.96) 2.32 (1.27, 4.21) 
  Systemic vasculitis 3 (8.6) 1.27 (0.42, 3.83) 1.43 (0.50, 4.13) 
  Systemic sclerosis 7 (36.8) 5.07 (2.46, 10.4) 5.15 (2.75, 9.67) 
  Vasculitis limited to skin 1 (7.1) 1.06 (0.16, 7.15) 1.15 (0.18, 7.55) 
  Dermatopolymyositis 1 (20.0) 2.96 (0.48, 18.2) 3.07 (0.43, 21.7) 
  Any of above 24(16.2) 2.32 (1.52, 3.54) 2.42 (1.60, 3.67) 
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  General obstetric population 37,425 (6.5) 1.00 1.00 
Small for gestational age (<10th percentiles)    
  Other systemic involvement of connective tissue 23 (9.8) 1.04 (0.67, 1.61)† 1.13 (0.72, 1.78)† 
  Systemic vasculitis 9 (10.6) 1.10 (0.52, 2.30)† 1.10 (0.52, 2.34)† 
  Systemic sclerosis 3 (5.7) 0.62 (0.19, 2.00)† 0.58 (0.17, 1.96)† 
  Vasculitis limited to skin 0 (0) - - 
  Dermatopolymyositis 2 (11.8) 1.41 (0.31, 6.43)† 1.17 (0.24, 5.57)† 
  Any of above 37 (9.1) 0.95 (0.67, 1.35)† 0.99 (0.69, 1.42)† 
  General obstetric population 93,644 (9.5) 1.00† 1.00† 
Admission to neonatal intensive care unit    
  Other systemic involvement of connective tissue 69 (29.4) 1.94 (1.56, 2.41) 1.55 (1.27, 1.89) 
  Systemic vasculitis 22 (25.9) 1.72 (1.19, 2.48) 0.93 (0.67, 1.28) 
  Systemic sclerosis 20 (37.7) 2.51 (1.77, 3.55) 1.32 (0.96, 1.82) 
  Vasculitis limited to skin 4 (16.7) 1.11 (0.45, 2.73) 1.02 (0.48, 2.14) 
  Dermatopolymyositis 6 (35.3) 2.37 (1.21, 4.64) 1.23 (0.69, 2.19) 
  Any of above 119 (29.1) 1.93 (1.64, 2.26) 1.33 (1.14, 1.55) 
  General obstetric population 150,353 (15.2) 1.00 1.00 
Severe neonatal morbidity    
  Other systemic involvement of connective tissue 19 (8.1) 1.85 (1.21, 2.83) 1.23 (0.86, 1.78) 
  Systemic vasculitis 16 (18.8) 4.27 (2.64, 6.91) 1.75 (1.20, 2.55) 
  Systemic sclerosis 12 (22.6) 5.14 (3.14, 8.41) 1.86 (1.27, 2.71) 
  Vasculitis limited to skin 1 (4.2) 0.97 (0.14, 6.74) 0.68 (0.08, 6.03) 
  Dermatopolymyositis 3 (17.7) 4.02 (1.46, 11.1) 1.20 (0.56, 2.57) 
  Any of above 49 (12.0) 2.73 (2.09, 3.58) 1.46 (1.17, 1.83) 
  General obstetric population 44,305 (4.5) 1.00 1.00 
* Adjusted for maternal age, country of birth, socio-economic status, maternal residence, chronic 
hypertension, pregestational diabetes, smoking during pregnancy, parity and plurality. Additional adjustment 
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for preterm birth was applied to severe neonatal morbidity, Apgar score at 5 minutes and admission to 
neonatal intensive care unit.  
† No convergence of GEE parameter estimates after 50 iterations in a ‘modified Poisson’ approach 
suggested by Zou. Odds ratio was reported instead. 
‡ Excludes planned births, i.e. by labor induction or prelabor caesarean delivery. 
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Table 4 Health service utilization outcomes for births by status of rare autoimmune diseases in NSW during 2001-2011 
 General 
obstetric 
population 
Any 
autoimmune 
disease 
Other systemic 
involvement of 
connective tissue 
Systemic 
vasculitis 
 
Systemic 
sclerosis 
Vasculitis 
limited to 
skin 
Dermato/ 
polymyositis 
 N=991,292 N=409 N=235 N=85 N=53 N=24 N=17 
Days of maternal hospital 
stay, 
    Mean (SD)     
       
       
4.9 (5.0) 
5.0 (3.0-6.0) 
6.5 (4.8) 
6.0 (4.0-7.0) 
6.4 (4.7) 
6.0 (4.0-7.0) 
6.8 (5.3) 
6.0 (4.0-
 
6.9 (5.8) 
6.0 (4.0-
 
5.6 (2.2) 
5.5 (5.0-7.0) 
7.8 (8.8) 
6.0 (4.0-8.0) 
    P value*  <0.001 <0.001 <0.001 <0.001 0.02 0.05 
No. antenatal admissions, 
 
       
    0 704,956 
 
198 (48.4) 117 (49.8) 44 (51.8) 23 (43.4) 12 (50.0) 3 (17.7) 
    1  181,197 
 
112 (27.4) 59 (25.1) 27 (31.8) 15 (28.3) 5 (20.8) 8 (47.1) 
    2-3  86,736 (8.8) 71 (17.4) 45 (19.2) 8 (9.4) 10 (18.9) 6 (25.0) 3 (17.7) 
    >=4  18,403 (1.9) 28 (6.9) 14 (6.0) 6 (7.1) 5 (9.4) 1 (4.2) 3 (17.7) 
    P value†  <0.001 <0.001 <0.001 <0.001 0.07 <0.001 
Obstetric care, n(%)         
    Tertiary hospital  446,088 
 
229 (56.1) 121 (51.5) 56 (65.9) 35 (66.0) 11 (47.8) 9 (52.9) 
    Urban hospital 368,970 
 
127 (31.1) 85 (36.2) 19 (22.4) 13 (24.5) 5 (21.7) 5 (29.4) 
    Rural hospital 174,792 
 
52 (12.8) 29 (12.3) 10 (11.8) 5 (9.4) 7 (30.4) 3 (17.7) 
    P value†  <0.001 0.05 <0.001 0.009 0.16 0.77 
Postpartum hospital 
admission for any cause, 
 
104,543 
(10.6) 85 (20.8) 40 (17.0) 22 (25.9) 14 (26.4) 4 (16.7) 7 (41.2) 
    P value†  <0.001 0.003 <0.001 <0.001 0.31 0.001 
Postpartum hospital 
admission for 
   
4,756 (0.5) 6 (1.5) 1 (0.4) 3 (3.5) 1 (1.9) 1 (4.2) 1 (5.9) 
    P value†  0.02 1.00 0.008 0.23 0.11 0.08 
Postpartum venous 
thromboembolism, n(%) 1,334 (0.1) 4 (1.0) 4 (1.7) 0 (0) 0 (0) 0 (0) 0 (0) 
    P value†  0.003 <0.001 1.00 1.00 1.00 1.00 
* Wilcoxon two-sample test for comparison of each autoimmune disease group to general obstetric population.  
† Chi-square test for comparison of each autoimmune disease group to general obstetric population.
